| Literature DB >> 25445397 |
Xiaoye Schneider-Yin1, Anne-Moon van Tuyll van Serooskerken2, Marko Siegesmund3, Philip Went4, Jasmin Barman-Aksözen1, Reno S Bladergroen2, Paul Komminoth5, Roy H E Cloots6, Véronique J Winnepenninckx6, Axel zur Hausen6, Markus Weber7, Ann Driessen6, Pamela Poblete-Gutiérrez8, Peter Bauer9, Christopher Schroeder9, Michel van Geel2, Elisabeth I Minder1, Jorge Frank10.
Abstract
Variegate porphyria (VP) and acute intermittent porphyria (AIP), the two most common types of acute porphyrias (AHPs), result from a partial deficiency of protoporphyrinogen oxidase (PPOX) and hydroxymethylbilane synthase (HMBS), respectively. A rare but serious complication in the AHPs is hepatocellular carcinoma (HCC). However, the underlying pathomechanisms are yet unknown. We performed DNA sequence analysis in cancerous and non-cancerous liver tissue of a VP and an AIP patient, both with HCC. In samples of both cancerous and non-cancerous liver tissues from the patients, we identified the underlying PPOX and HMBS germline mutations, c.1082dupC and p.G111R, respectively. Additionally, we detected a second somatic mutation, only in the cancer tissue i.e., p.L416X in the PPOX gene of the VP patient and p.L220X in the HMBS gene of the AIP patient, both located in trans to the respective germline mutations. Both somatic mutations were not detected in 10 non-porphyria-associated HCCs. Our data demonstrate that in the hepatic cancer tissue of AHP patients, somatic second-hit mutations result in nearly complete inactivation of the enzymes catalyzing major steps in the heme biosynthetic pathway. Both PPOX and HMBS, which might act as tumor suppressors, play a crucial role in the development of HCC in these individuals.Entities:
Keywords: Acute intermittent porphyria; Hepatocellular carcinoma; Tumor suppressor; Variegate porphyria
Mesh:
Substances:
Year: 2014 PMID: 25445397 DOI: 10.1016/j.jhep.2014.11.029
Source DB: PubMed Journal: J Hepatol ISSN: 0168-8278 Impact factor: 25.083